Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ANI Pharmaceuticals announced the commercial launch of 50mg and 150mg fenofibrate capsules USP (the authorized generic of Lipofen) in the ANI label.
Subscribe to our email newsletter
The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second quarter of 2016.
In 2015 the authorized generic for Lipofen (fenofibrate capsules 50mg and 150mg USP) generated $21.9 million in revenues.
ANI president and CEO Arthur Przybyl said: "We are pleased to have successfully transitioned the fenofibrate authorized generic to the ANI label on schedule."
About Lipofen Capsules
Lipofen (fenofibrate capsules) is a peroxisome proliferator receptor alpha (PPARa) activator indicated as an adjunct to diet: to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and for treatment of adult patients with severe.